论文部分内容阅读
改变终末分化细胞的可塑性使其重新具有多能性是生物医学研究在21世纪的重要突破。人诱导多能干细胞(Human-induced plu r ipotent stem cells,i PSCs)的出现不仅在一定程度上避免了胚胎干细胞在技术、伦理和免疫排斥反应上的限制,而且为基础医学研究和再生医学研究提供了新的工具。2002年,世界卫生组织统计显示,心血管疾病已经成为非感染性死亡的首要原因,并有逐年增加的趋势。由于心血管疾病研究方法上限制,如动物模型不能很好反映人的疾病状态、人源心肌样本缺少及原代心肌细胞获得和培养困难等,为该病的研究和相关疾病发病机制的阐明提供了障碍。目前研究显示,i PSCs在心肌损伤修复,心血管疾病相关模型的建立和治疗药物筛选等方面表现出一定的优势和应用前景。本文就i PSCs在心血管疾病中的应用做如下综述。
Changing the plasticity of terminally differentiated cells to their pluripotency is an important breakthrough in biomedical research in the 21st century. The emergence of human-induced pluotocyte stem cells (iPSCs) not only to some extent to avoid the technical, ethical and immune rejection of embryonic stem cells restrictions, but also for basic medical research and regenerative medicine research New tools are provided. In 2002, WHO statistics showed that cardiovascular disease has become the leading cause of non-infectious death and has been increasing year by year. Due to limitations in the research methods of cardiovascular diseases, such as the animal model can not reflect the human disease status, the lack of samples of human cardiac muscle and the difficulty of obtaining and culturing primary cardiomyocytes, provide the research of the disease and the elucidation of the pathogenesis of related diseases Obstacle. The current study shows that iPSCs have some advantages and applications in the field of myocardial injury repair, the establishment of models of cardiovascular diseases and the screening of therapeutic drugs. This article reviews the use of i PSCs in cardiovascular disease.